LTZ Therapeutics Raises $38 Million in Support of Advancing Myeloid Engager Immunotherapy Pipeline
– Erin Lavelle Joins LTZ’s Board of Directors to Guide Strategic Operations – REDWOOD CITY, Calif. & SHENZHEN, China–(BUSINESS WIRE)–LTZ Therapeutics, a clinical-stage, immunotherapy-focused biotechnology company, today announced the completion of an oversubscribed $38 million…